75N95021Q00376

Submitted by NIDA_Section on
Post Date/ Solicitation Issue Date
Closing Response Date
Proposed Award Date
Project Title
NGLY1 Deficiency Neural Stem Cell Proteomic Analysis
Contracting Office
National Institute on Drug Abuse (NIDA)

Contact Points

Primary Contract Specialist

Scott
Duernberger
scott.duernberger@nih.gov

Secondary Contracting Officer

Kenneth
Goodling
kgoodlin@nida.nih.gov
NAICS Code Number
541714
The purpose is to establish biomarkers and potential drug targets for NGLY1 deficiency we need to perform high-throughput proteomic analysis of patient derived neural stem cells and CRISPR corrected isogenic controls.
Small Business Size Standard
1000 Employees
FPDS Classification Code
N/A
Estimated Period of Performance
6 weeks
Delivery of Goods
N/A
Competition Status
Non-Competitive
Vendor Name
Poochon Scientific LLC
Vendor Address
5350 Partners CT STE, Frederick, Maryland, 21703
Single-Sole Source Determination
The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted. Poochon Scientific LLC is the only organization that can provide the proteomic analysis for the research project. Poochon Scientific has the required analysis requirements and optimized parameters for this project.

In accordance with FAR part 10, the market research was conducted to reach this determination. Specifically, reviewed the results of recent market research undertaken to meet similar or identical requirements. Therefore, only Poochon Scientific LLC is capable of meeting the needs of this requirement.
Background/Description of Requirement
NCATS focuses on getting more treatments to more patients more quickly. Several thousand genetic diseases affect humans, of which only about 500 have any treatment. NCATS is directly addressing this problem by discovering new technologies and other approaches that could greatly accelerate the process of developing and deploying solutions that can be used by all translational researchers. Within NCATS, the TDB biology group works to encourage and speed the development of new treatments for diseases with high-unmet medical needs. This acquisition specifically addresses the new therapeutic for NGLY1 rare disease project, which specifically applies breakthroughs in translational science to advancing new treatments for rare diseases. NGLY1 deficiency is a rare disease and the first known cogenital disease of deglycosylation. Currently there are about 70 patients known to have NGLY1 deficiency, and there is currently no standard therapeutic option for these patients. To identify potential drug targets or biomarkers associated with the disease, TDB Biology is requesting a contractor perform high-throughput quantitative proteomics. We are performing RNA-seq on patient derived neural stem cells with isogenic controls, to validate our transcriptomic results high-throughput quantitative proteomics is needed.

Interested parties may identify in writing their interest and capability in response to this requirement. Responses to this notice shall contain sufficient information to establish the interested parties’ bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.

All responses must be received by closing date and must reference the announcement. Responses may be submitted electronically to the attention of the contract specialist. Fax responses will not be accepted.

All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency.